Roctavian Market Report 2026

Roctavian Market Overview

• The Roctavian market growth in the historic period has been driven by improvements in gene delivery technologies, increasing clinical understanding of hemophilia genetics • Market expansion is supported by increasing investments in curative genetic therapies, growing demand for durable hemophilia treatments • Growth Driver: Rising Prevalence Of Hemophilia Driving Growth In The Market • Market Trend: Regulatory Approvals Driving Market Expansion • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Roctavian Market?

Roctavian is a gene therapy developed to treat hemophilia A, a genetic disorder caused by a deficiency in clotting factor VIII. The treatment delivers a functional copy of the factor VIII gene, enabling the body to produce the clotting factor naturally. It offers the potential for long-term or permanent relief from the condition. The main clinical indications of roctavian are severe hemophilia A, prophylactic therapy, patients without factor VIII inhibitors, and patients with neutralizing antibodies to AAV5. Severe hemophilia A refers to a genetic disorder in which a person has very low levels or an absence of clotting factor VIII, which is essential for blood clotting. It is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, catering to various end users, including hospitals, specialty clinics, homecare providers, and research institutions.

What Is The Roctavian Market Growth Forecast?

The growth in the forecast period can be attributed to increasing investments in curative genetic therapies, growing demand for durable hemophilia treatments, expansion of personalized medicine frameworks, rising adoption of value-based reimbursement models, continued innovation in vector engineering. Major trends in the forecast period include increasing adoption of one-time gene therapy treatments, rising focus on long-term disease modification, growing use of advanced viral vector technologies, expansion of precision genetic diagnostics integration, enhanced monitoring of post-therapy outcomes.

Global Roctavian Market Segmentation

1) By Clinical Indication: Severe Hemophilia A, Prophylactic Therapy, Patients Without Factor VIII Inhibitors, Patients With Neutralizing Antibodies To AAV5 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 3) By End User: Hospitals, Specialty Clinics, Homecare Providers, Research Institutions

What Are The Drivers Of The Roctavian Market?

The increase in the prevalence of hemophilia is expected to propel the growth of the roctavian market going forward. Hemophilia is a genetic disorder causing improper blood clotting due to a deficiency in clotting factors, typically treated with replacement therapy. The prevalence of hemophilia is increasing due to improved diagnosis, awareness, and genetic testing identifying more cases. Roctavian is used to treat hemophilia A by providing a one-time gene therapy infusion that enables the body to produce its own Factor VIII, reducing bleeding episodes and the need for regular clotting factor treatments. For instance, in October 2025, according to a report published by the World Federation of Hemophilia Report, a Canada-based non-profit organization, the data shows a 6% increase in the global identification of people with hemophilia, a 6% increase in the identification of people with VWD, and a 9% increase in the identification of other inherited bleeding disorders. Therefore, the increase in the prevalence of hemophilia is driving the growth of the roctavian industry. The rising healthcare investments are expected to fuel the growth of the roctavian market going forward. Healthcare investments involve allocating capital into healthcare-related sectors, such as pharmaceuticals, medical devices, and digital health, to support growth and innovation. Increasing healthcare investments are driven by rising demand due to aging populations, technological advancements, and growing chronic diseases. Healthcare investments in roctavian are used to support its research, clinical trials, regulatory approvals, manufacturing, and market access strategies to ensure widespread availability and effective treatment. For instance, in November 2025, according to Organisation for Economic Co operation and Development, a France-based intergovernmental organization, reported that in 2023, public sources financed on average 72% of healthcare spending in OECD countries. Therefore, the rising healthcare investments are driving the growth of the roctavian industry.

Key Players In The Global Roctavian Market

Major companies operating in the roctavian market are BioMarin Pharmaceutical Inc.

Global Roctavian Market Trends and Insights

Major companies operating in the Roctavian market are focusing on developing innovative solutions, such as advanced gene therapies, to meet the rising demand for long-term, infusion-free treatment options for severe hemophilia A. Gene therapy introduces a functional genetic material into the patient’s cells to help them produce essential proteins that traditional factor-replacement therapies must supply externally. For instance, in June 2023, BioMarin Pharmaceutical Inc., a US-based biotechnology company, received FDA approval for Roctavian, an innovative gene therapy introduced after 2022 for adults with severe hemophilia A. Roctavian uses an adeno-associated viral vector to deliver a working copy of the Factor VIII gene, enabling the body to produce its own clotting protein. It significantly reduces bleeding episodes, minimizes reliance on regular prophylactic infusions, and offers durable therapeutic benefits based on long-term clinical data. The approval was supported by the GENEr8-1 trial, which demonstrated substantial reductions in annualized bleeding rates, marking a transformative shift from frequent infusions to a one-time treatment approach.

Regional Insights

North America was the largest region in the roctavian market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Roctavian Market?

The roctavian market consists of sales of coagulation factor VIII products, immunosuppressive medications, and recombinant factor IX products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Roctavian Market Report 2026?

The roctavian market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the roctavian industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.